FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to arthrology and therapy, and may be used for treating arthritis in a mammal A method consists in the fact that N-(4-(4-((4'-chlor(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulphanyl)methyl)propyl)amino)-3-nitrobenzolsulphonamide is introduced into patient in need thereof.
EFFECT: invention enables reducing doses of the preparations used to the integrated therapy of arthritis ensured by lymphocytic immune suppression.
3 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING ARTHRITIS | 2008 |
|
RU2526201C2 |
| METHOD OF OBTAINING APOPTOSIS STIMULATOR ABT-263 | 2009 |
|
RU2514935C2 |
| BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR TREATING CANER AND IMMUNE DISEASES | 2010 |
|
RU2542994C2 |
| APOPTOSIS INDUCING AGENTS FOR TREATING CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2538965C2 |
| APOPTOSIS-INDUCING PREPARATIONS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2009 |
|
RU2527450C2 |
| APOPTOSIS-INDUCING AGENTS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2535203C2 |
| APOPTOSIS INDUCING AGENTS FOR TREATING CANCER, IMMUNE AND AUTOIMMUNE DISEASES | 2011 |
|
RU2568611C2 |
| PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF BCL-2 FAMILY INHIBITOR | 2010 |
|
RU2711359C2 |
| APOPTOSIS-INDUCING MEDICATIONS FOR TREATING CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2554346C2 |
| APOPTOSIS-INDUCING AGENTS FOR TREATING MALIGNANT TUMOURS AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2573832C2 |
